Interferon-Beta in the Treatment of Multiple Sclerosis: Do Clinical Data Support the Existence of a Ceiling Effect?

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.21, Iss.4, 2001-04, pp. : 307-318

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 1, 2009-03 ,pp. : 14-28

Bentham Science Publishers

Access to resources Recommend Favorite

Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a: Modelling the Clinical and Economic Implications

By Guo Shien Bozkaya Duygu

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 39-53

Adis International

Access to resources Recommend Favorite

Neutralising Antibodies to Interferon- in the Treatment of Multiple Sclerosis: Cause for Concern?

By Paszner B.

CNS Drugs, Vol. 11, Iss. 3, 1999-03 ,pp. : 225-243

Adis International

Access to resources Recommend Favorite

Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 10, Iss. 2, 2010-06 ,pp. : 161-167

Bentham Science Publishers

Access to resources Recommend Favorite

Cannabinoids in Multiple Sclerosis: Do They Have a Therapeutic Role?

By Killestein J. Uitdehaag B.M.J. Polman C.H.

Drugs, Vol. 64, Iss. 1, 2004-01 ,pp. : 1-11

Adis International

Access to resources Recommend Favorite